Methodological issues and recommendations for systematic reviews of prognostic studies: An example from cardiovascular disease

Systematic Reviews

Volumn 3, Issue 1, 2014, Pages

  Dretzke, Janine ^a   Ensor, Joie ^a   Bayliss, Sue ^a   Hodgkinson, James ^a   Lordkipanidzé, Marie ^b,c   Riley, Richard D ^d   Fitzmaurice, David ^a   Moore, David ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

^d KEELE UNIVERSITY   (United Kingdom)

Author keywords

Aspirin resistance; Cardiovascular disease; Prognostic factor; Prognostic utility; Quality assessment; Reporting bias; Search strategy; Study selection; Systematic review methodology

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; DATA BASE; DIAGNOSTIC ACCURACY; HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; NOMENCLATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; QUALITY CONTROL; SEARCH ENGINE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE FUNCTION; TREATMENT OUTCOME; TYPES OF ARTICLE OR STUDY; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; LITERATURE; PROGNOSIS;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; HUMANS; PROGNOSIS; REVIEW LITERATURE AS TOPIC;

EID: 84927946384     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-140     Document Type: Article

References (41)

1. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, Briggs A, Udumyan R, Moons KGM, Steyerberg EW, Roberts I, Schroter S, Altman DG, Riley RD. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ 2013, 346:e5595. 10.1136/bmj.e5595, 3565687, 23386360.
2. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, Hemingway H. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013, 10:e1001380. 10.1371/journal.pmed.1001380, 3564757, 23393429.
3. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009, 100:1219-1229. 10.1038/sj.bjc.6604999, 2676559, 19367280.
4. Hayden JA, Chou R, Hogg-Johnson S, Bombardier C. Systematic reviews of low back pain prognosis had variable methods and results: guidance for future prognosis reviews. J Clin Epidemiol 2009, 62:781-796. 10.1016/j.jclinepi.2008.09.004, 19136234.
5. Rector TS, Taylor BC, Wilt TJ. Chapter 12: systematic review of prognostic tests. J Gen Intern Med 2012, 27:94-101.
6. Cochrane Prognosis Methods Group [http://prognosismethods.cochrane.org/].
7. Moons KGM, De Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, Reitsma JB, Collins GS. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med 2014, 11(10):e1001744. doi:10.1371/journal.pmed.1001744, 10.1371/journal.pmed.1001744, 4196729, 25314315.
8. Dretzke J, Riley R, Lordkipanidzé M, Jowett S, O'Donnell J, Ensor J, Moloney E, Price M, Raichand S, Hodgkinson J, Bayliss S, Fitzmaurice D, Moore D. The prognostic and diagnostic utility of tests of platelet function for the detection of " aspirin resistance" in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. Health Technol Assess 2014, in press.
9. Raichand S, Moore D, Riley RD, Lordkipanidze M, Dretzke J, O'Donnell J, Jowett S, Bayliss S, Fitzmaurice DA. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease. Syst Rev 2013, 2:16. 10.1186/2046-4053-2-16, 3600664, 23442317.
10. Canivano PL, Garcia YC. Resistance to aspirin: prevalence, mechanisms of action and association with thromboembolic events. A narrative review. Farm Hosp 2010, 34:32-43. 10.1016/j.farma.2009.08.002, 20144820.
11. Krasopoulos G, Brister SJ, Scott BW, Buchanan MR. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336:195-198. 10.1136/bmj.39430.529549.BE, 2213873, 18202034.
12. Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, Papp E, Lupkovics G, Szapary L. Aspirin resistance: focus on clinical endpoints. J Cardiovasc Pharmacol 2008, 52:475-484. 10.1097/FJC.0b013e31818eee5f, 19034037.
13. Snoep JD, Hovens MM, Eikenboom JC, Van Der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007, 167:1593-1599. 10.1001/archinte.167.15.1593, 17698681.
14. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events-a meta-analysis. Int J Cardiol 2008, 128:166-171. 10.1016/j.ijcard.2007.12.010, 18242733.
15. Li J, Song M, Jian Z, Guo W, Chen G, Jiang G, Wang J, Wu X, Huang L. Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence. J Atheroscler Thromb 2014, 21:239-247. 10.5551/jat.19521, 24201035.
16. Wisman PP, Roest M, Asselbergs FW, de Groot PG, Moll FL, Van Der Graaf Y, de Borst GJ. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2014, 12:736-747.
17. Geersing GJ, Bouwmeester W, Zuithoff P, Spijker R, Leeflang M, Moons KG. Search filters for finding prognostic and diagnostic prediction studies in MEDLINE to enhance systematic reviews. PLoS One 2012, 7:e32844. 10.1371/journal.pone.0032844, 3290602, 22393453.
18. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655. 10.1161/01.CIR.0000013777.21160.07, 11940542.
19. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM., QUADAS-2 Group QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536. 10.7326/0003-4819-155-8-201110180-00009, 22007046, QUADAS-2 Group.
20. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006, 144:427-437. 10.7326/0003-4819-144-6-200603210-00010, 16549855.
21. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses 2014, Canada: Department of Epidemiology and Community Medicine, University of Ottawa, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
22. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013, 158:280-286. 10.7326/0003-4819-158-4-201302190-00009, 23420236.
23. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834. 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8, 9921604.
24. Perneger TV. Estimating the relative hazard by the ratio of logarithms of event-free proportions. Contemp Clin Trials 2008, 29:762-766. 10.1016/j.cct.2008.06.002, 18639651.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
26. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC, Wilson PW., American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416. 10.1161/CIRCULATIONAHA.109.192278, 2956982, 19364974, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council.
27. Chatterley T, Dennet L. Utilisation of search filters in systematic reviews of prognosis questions. Health Info Libr J 2012, 29:309-322. 10.1111/hir.12004, 23176027.
28. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965. 10.1016/S0735-1097(02)03014-0, 12651041.
29. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM. Results of the BRAT study-a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000, 16:1385-1390.
30. Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, Meric M, Nisanci Y. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006, 22:103-110. 10.1007/s11239-006-8952-4, 17008975.
31. Lefebvre C, Glanville J, Wieland LS, Coles B, Weightman AL. Methodological developments in searching for studies for systematic reviews: past, present and future?. Syst Rev 2013, 2:78. 10.1186/2046-4053-2-78, 4015986, 24066664.
32. De Jonge RC, Van Furth AM, Wassenaar M, Gemke RJ, Terwee CB. Predicting sequelae and death after bacterial meningitis in childhood: a systematic review of prognostic studies. BMC Infect Dis 2010, 10:232. 10.1186/1471-2334-10-232, 2921388, 20684796.
33. Verkerk K, Luijsterburg PA, Miedema HS, Pool-Goudzwaard A, Koes BW. Prognostic factors for recovery in chronic nonspecific low back pain: a systematic review. Phys Ther 2012, 92:1093-1108. 10.2522/ptj.20110388, 22595238.
34. Churchill R, Caldwell D, Savovic J. Developing ROBIS - A New Tool to Assess the Risk of Bias in Systematic Reviews 2013, Bristol: University of Bristol, [http://gtr.rcuk.ac.uk/project/F489B8DD-D7C2-41B5-B54D-9F3CD722133E].
35. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, Wozney L. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev 2013, 2:71. 10.1186/2046-4053-2-71, 3930077, 24007720.
36. Dahlen JR, Price MJ, Parise H, Gurbel PA. Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thromb Haemost 2013, 109:808-816.
37. Steyerberg EW, Moons KG, Van Der Windt DA, Hayden JA, Perel P, Schroter S, Riley RD, Hemingway H, Altman DG. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013, 10:e1001381. 10.1371/journal.pmed.1001381, 3564751, 23393430.
38. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002, 25:76-97. 10.1177/0163278702025001006, 11868447.
39. Abo-Zaid G, Sauerbrei W, Riley RD. Individual participant data meta-analysis of prognostic factor studies: state of the art?. BMC Med Res Methodol 2012, 12:56. 10.1186/1471-2288-12-56, 3413577, 22530717.
40. Ensor J, Riley RD, Moore D, Bayliss S, Jowett S, Fitzmaurice DA. Protocol for a systematic review of prognostic models for the recurrence of venous thromboembolism (VTE) following treatment for a first unprovoked VTE. Syst Rev 2013, 2:91. 10.1186/2046-4053-2-91, 3852155, 24089702.
41. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001, 323:224-228. 10.1136/bmj.323.7306.224, 1120839, 11473921.